GO
| HSI1 | 25,409.55 | -241.32 | 90.45B |
| HSCEI1 | 8,433.28 | -121.75 | 21.27B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-04 11:33:11 CLSA issued a research report on HUTCHMED (00013.HK), which licensed the ex-China rights of its KRAS-EGFR ATTC candidate HMPL-A830 to GSK, receiving an upfront payment of USD110 million and milestone payments of up to USD1.3 billion. The broker viewed the transaction represents strong recognition of the company's ATTC platform by a multinational pharmaceutical company. Further proof-of-concept data for the ATTC portfolio and additional partnerships are key catalysts worth monitoring, CLSA noted. The broker reiterated the company's Outperform rating with TP maintained at HKD29.5. ~ AASTOCKS Financial News Website: www.aastocks.com | |